ErbB2 _ HER2 _ CD340 Antibody ( FITC )
- Known as:
- ErbB2 _ HER2 _ CD340 Antibody ( fluorecein )
- Catalog number:
- 10004-R511F
- Product Quantity:
- 100Tests
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- ErbB2 _ HER2 CD340 Antibody ( FITC )
Related genes to: ErbB2 _ HER2 _ CD340 Antibody ( FITC )
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: ErbB2 _ HER2 _ CD340 Antibody ( FITC )
Related articles to: ErbB2 _ HER2 _ CD340 Antibody ( FITC )
- Despite the success of HER2-targeted antibody-drug conjugates (ADCs) in common cancers, there is a lack of real-world evidence regarding their role in rare tumors where gene amplification by next-generation sequencing (NGS) may serve as a more precise driver than traditional protein expression. In this retrospective case series at Bumrungrad International Hospital, we describe three patients with -amplified rare tumors-periampullary carcinoma (immunohistochemistry [IHC] 2+, 77 copies by NGS), salivary duct carcinoma (IHC 3+, 33.7 copies), and poorly differentiated carcinoma (IHC 1+, 16.8 copies)-treated with trastuzumab emtansine (T-DM1) and/or trastuzumab deruxtecan (T-DXd). Despite heterogeneous histology and low-to-equivocal IHC scores, all achieved meaningful objective responses: a 301-day partial remission, a complete intracranial and systemic response using sequential ADC therapy (T-DXd followed by T-DM1 after toxicity), and a near-complete response in an IHC 1+ (HER2-low) tumor. These results demonstrate that high-level gene amplification can predict ADC efficacy regardless of IHC status or rare histology. Our findings underscore the value of integrating NGS into diagnostic workflows at the point of care to identify 'hidden' responders and support the feasibility of ADC sequencing in the management of treatment-limiting toxicities. - Source: PubMed
Publication date: 2026/04/30
Jitthiang PiyanootPhandthong RattanavitPhikulsod PloyploenJirawatnotai SiwanonKiatikajornthada NarongsakSuwanrusme Harit - was to evaluate the applicability of radioimmunoconjugates (RIC) of nanobodies against PD-L1 and HER2/ neu for the diagnosis and therapy of malignant tumors. - Source: PubMed
Publication date: 2026/04/30
Avrov K OShatik S VShashkova O APinevich A ATerekhina L AGryazeva I VZaitsev V VBerlina M AStanzhevsky A ASamoylovich M P - Obesity's impact on breast cancer prognosis may depend on molecular subtype, yet there is limited research on premenopausal women with HR+HER2- breast cancer. In this study, we included 5,094 premenopausal women with HR+HER2- early-stage breast cancer who underwent radical surgery at 42 breast centers across China between 2016 and 2021. Patients were categorized into four BMI groups: underweight (UW), normal weight (NW), overweight (OW), and obese (OB). Using propensity score matching (PSM) to adjust for confounding factors, we compared disease-free survival (DFS) across BMI groups with Kaplan-Meier curves and performed multivariate Cox regression analysis to evaluate the effect of obesity on prognosis. Our results showed that obese patients had significantly worse DFS compared to those who were UW, NW, or OW (p = 0.013). After adjusting for clinicopathologic factors and treatment, obesity remained an independent prognostic factor for DFS in premenopausal HR+/HER2- patients (p = 0.043). After 1:1 PSM, OW/OB patients receiving selective estrogen receptor modulators (SERMs) alone had significantly worse DFS compared to UW/NW patients (p = 0.022), whereas OW/OB patients treated with SERMs or aromatase inhibitors (AIs) in combination with ovarian function suppression (OFS) showed no significant difference in DFS from UW/NW patients. In addition, Restricted Cubic Splines (RCS) analysis demonstrated that the risk of recurrence increases with BMI in OW/OB patients. Collectively, these findings indicate that obesity may act as an independent adverse prognostic factor for DFS in premenopausal women with HR+/HER2- breast cancer. Importantly, our results also suggest that OFS may attenuate the detrimental effect of obesity in patients treated with SERMs. - Source: PubMed
Publication date: 2026/05/18
Lian WeibinHong ChengyeWang ChuanChen Debo - The genomic landscape of p16 + oropharyngeal cancer (OPX), particularly in early-stage disease, remains limited. Better understandings of the differences between early and late-stage disease may improve elucidation of risk factors that warrant de-escalation. This analysis aims to substantially contribute to existing knowledge of the genomic landscape in an exclusively stage group I/II cohort. - Source: PubMed
Publication date: 2026/05/16
Brown Matthew HMendes William SSong YangShetty Amol CWitek Matthew EMehra RaneeHatten Kyle MTaylor Rodney JMoyer Kelly FWolf Jeffrey STyer Tiffani NSteacy Katarina JEggleston CaitlinDatnow ClaudiaGaykalova Daria ARegine William FRen LeiTran Phuoc TFerris Matthew JMolitoris Jason K - Hereditary cancer risk assessment has predominantly focused on HER2-negative breast cancer (BC), with limited characterization of germline pathogenic variants (GPVs) in HER2-positive disease. This study aimed to delineate the prevalence, clinicopathological correlates, and clinical implications of GPVs in a cohort of HER2-positive BC patients. - Source: PubMed
Zhou LijiaNi MengqianYang AnliZhou QingruWang DainingDun ShuXu FeiHuang JiajiaBi XiwenXia WenHong RuoxiZheng QiufanChen MeitingJiang KuikuiTang JunWang XiYuan ZhongyuWang ShusenShi YanxiaWang FangAn Xin